{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Prestige Consumer Healthcare, Inc.
Prestige Consumer Healthcare Stock Hits New 52-Week Low at $59.62
Prestige Consumer Healthcare, Inc. has reached a new 52-week low, trading at USD 59.62 as of October 31, 2025. The company has seen a 7.75% decline over the past year, contrasting with the S&P 500's performance. Financial metrics show mixed results, with high institutional ownership and recent low quarterly sales figures.
Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Landscape
Prestige Consumer Healthcare, Inc. has adjusted its valuation, showcasing a P/E ratio of 20 and a price-to-book value of 2.48. The company demonstrates solid profitability with a ROCE of 12.76% and ROE of 12.16%, positioning it competitively within the pharmaceuticals and biotechnology sector.
Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Metrics
Prestige Consumer Healthcare, Inc. has adjusted its valuation within the pharmaceuticals and biotechnology sector, with key metrics indicating operational efficiency and profitability. The company's performance has fluctuated, showing a decline over the past year compared to the broader market, highlighting challenges in the current environment.
Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?
As of October 17, 2025, Prestige Consumer Healthcare, Inc. is considered overvalued with a shift in valuation grade from very attractive to attractive, reflected by high P/E, Price to Book, and EV to EBITDA ratios compared to peers, alongside a year-to-date return of -20.49% versus the S&P 500's 13.30% gain.
Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?
As of October 17, 2025, Prestige Consumer Healthcare, Inc. is considered overvalued with a P/E ratio of 20 compared to the peer average of 15.85, a PEG ratio of 3.01, and an EV to EBITDA of 14.39, while its stock has underperformed the S&P 500 with a return of -14.12%.
Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?
As of October 17, 2025, Prestige Consumer Healthcare, Inc. is considered overvalued with a P/E ratio of 20 and an EV to EBITDA of 14.39, underperforming the S&P 500 with a year-to-date return of -20.49%.
Prestige Consumer Healthcare Hits New 52-Week Low at $60.15
Prestige Consumer Healthcare, Inc. has reached a new 52-week low, reflecting a notable decline in its performance over the past year. The company, with a market capitalization of USD 3,511 million, has struggled with modest growth and reported its lowest quarterly net sales and operating profit levels.
Prestige Consumer Healthcare Stock Hits New 52-Week Low at $61.29
Prestige Consumer Healthcare, Inc. has reached a new 52-week low, trading at USD 61.29 as of September 30, 2025. The company has seen a 5.01% decline over the past year, with stagnant net sales and operating profit. Its market capitalization stands at USD 3,511 million, with a P/E ratio of 20.00.
Is Prestige Consumer Healthcare, Inc. technically bullish or bearish?
As of July 31, 2025, Prestige Consumer Healthcare, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 with a year-to-date return of -17.92% compared to the S&P 500's 12.22%.
Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?
As of August 7, 2025, Prestige Consumer Healthcare, Inc. is considered an attractive investment due to its undervalued metrics, including a P/E ratio of 20, compared to peers, despite recent stock performance lagging behind the S&P 500.
Prestige Consumer Healthcare Hits 52-Week Low at USD 61.94
Prestige Consumer Healthcare, Inc. recently hit a 52-week low, reflecting ongoing struggles in its performance, which has declined over the past year. The company has a market capitalization of USD 3,511 million, a P/E ratio of 20.00, and reported low quarterly net sales and profits, indicating modest long-term growth.
Is Prestige Consumer Healthcare, Inc. technically bullish or bearish?
As of June 11, 2025, the trend is mildly bullish due to daily moving averages, but caution is advised from short-term bearish signals in the weekly MACD and KST, while longer-term indicators remain positive.
Who are in the management team of Prestige Consumer Healthcare, Inc.?
As of March 2022, the management team of Prestige Consumer Healthcare, Inc. includes Mr. Ronald Lombardi as Chairman, President, and CEO, with Dr. Gary Costley as Lead Independent Director and several Independent Directors: Mr. John Byom, Mr. Christopher Coughlin, Ms. Sheila Hopkins, and Mr. James Jenness. They oversee the company's operations and strategic direction.
What does Prestige Consumer Healthcare, Inc. do?
Prestige Consumer Healthcare, Inc. markets and distributes over-the-counter healthcare products and operates in the small-cap Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $297 million and a net profit of $50 million, with a market cap of approximately $4.48 billion.
How big is Prestige Consumer Healthcare, Inc.?
As of Jun 18, Prestige Consumer Healthcare, Inc. has a market capitalization of $4.48 billion, with net sales of $1.14 billion and a net profit of $214.61 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
